Our drug metabolism and pharmacokinetics (DMPK) group offers a comprehensive selection of in vivo and in vitro DMPK services to help clients manage their drug discovery and development programs. Our highly trained scientific staff offer both standard regulatory-driven study designs and innovative approaches to unique drug development issues. Our senior scientists each have over 20 years of experience as study directors and principal investigators. The primary focus of the DMPK group is to provide our clients with the highest quality studies and reports along with expert consultation.
In Vivo Capabilities
GLP-compliant or non-GLP studies
Pharmacokinetic studies in standard biological models
Pharmacokinetic modeling (classically and physiologically based)
Discovery pharmacokinetic screening
Oral and percutaneous bioavailability studies
Radiolabeled studies
Tissue distribution and mass balance studies
Drug-drug interactions (induction and inhibition)
Metabolite profiling and metabolite identification
Biomarkers of exposure
In situ and isolated perfused organs (kidney, liver, intestine)
Specialized cannulations (vascular, biliary, and lymphatic)
In Vitro Capabilities
CYP inhibition (reversible and mechanism-based)
CYP induction (with optional cytotoxicity, mRNA expression, and Western blots)
CYP reaction phenotyping (HLM or rhCYPs)
Intestinal permeability in Caco-2 cells (Pgp substrate and/or inhibitor)
Metabolite profiling and identification in hepatocytes, or microsomes, or S9
Metabolic stability in hepatocytes or microsomes
Protein binding (equilibrium dialysis)
Cytotoxicity in hepatocytes (necrotic or apoptotic)
